Roland B. Walter
Fred Hutchinson Cancer Rearch Center
United States of America
Dr. Walter is a UW associate professor of medicine in the Division of Hematology, an assistant member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and a UW adjunct associate professor of epidemiology. His clinical and research interests focus around acute myeloid leukemia (AML). Education & Training MD: University of Zürich, Zürich, Switzerland, 1990-1997 PhD: University of Washington, Seattle, WA, 2004-2006 Internship and Residency, Internal Medicine: Kantonsspital, Chur, and University Hospital, Zürich, Switzerland, 1997-2002 Clinical Fellowship, Hematology: University of Washington, Seattle, WA, 2005-2007 Research Fellowship: Fred Hutchinson Cancer Research Center, Seattle, WA, 2002-2007
Clinical and laboratory research in acute myeloid leukemia, with a particular interest in antibody-based therapeutics.
Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first and second complete remission. Blood. 2013;122(10):1813-1821.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HM, Estey EH. Prediction of early death following induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011;29(33):4417-4424.
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM. Impact of pre-transplant minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29(9):1190-1197.
Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study. J Clin Oncol 2010;28(10):1766-1771.
Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005:105(3):1295-1302.